Abstract
The magnitude and duration of the effect of dexamethasone on systolic blood pressure has been examined in 13 very preterm infants (median gestational age 25 weeks). All had chronic lung disease (CLD). To exclude any effect of CLD on blood pressure each infant acted as his or her own control. Systolic blood pressure increased in all infants (P<0.01) and remained elevated for at least 48h following cessation of therapy. The median maximum increase in blood pressure was 24 mm Hg (range 13–49 mmHg) and occurred on day 4 (median, range 2–10) of treatment. One infant developed hypertensive encephalopathy. These results demonstrate the need to monitor infants with CLD throughout steroid therapy and preferably for some days after it has ceased.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CLD:
-
chronic lung disease
References
Abman SH (1984) Systemic hypertension in infants with bronchopulomary dysplasia. J Pediatr 104:928–931
Avery GB, Fletcher AB, Kaplan M, Brudno DS (1985) Controlled trial of dexamethasone in respiratory-dependent infants with bronchopulmonary dyspolasia. Pediatrics 75:106–111
Cummings JJ, D'Eugenio DB, Gross SJ (1989) A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 320:1505–1510
Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ (1989) Dexamathasone therapy for chronic lung disease in ventilator-and oxygen-dependent infants: a controlled trial. J Pediatr 115: 979–983
Tan KL (1988) Blood pressure in very low birthweight infants in the first 70 days of life. J Pediatr 112:266–270
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greenough, A., Emery, E.F. & Gamsu, H.R. Dexamethasone and hypertension in preterm infants. Eur J Pediatr 151, 134–135 (1992). https://doi.org/10.1007/BF01958959
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01958959